Tolazoline hydrochloride

Generic Medicine Info
Indications and Dosage
Pulmonary hypertension
Child: Neonate: 200 mcg/kg diluted with 0.5-1 ml of sodium chloride 0.9% for inj.

Pulmonary hypertension
Child: Neonate: Initially 1 mg/kg by IV inj over 2-5 min, followed by continuous IV infusion of 200 mcg/kg/hr (diluted with glucose 5% or sodium chloride 0.9%) if required. Monitor BP closely. Doses >300 mcg/kg/hr associated with cardiotoxicity and renal failure.

Peripheral vascular disease
Adult: 25-50 mg 4 times daily.

Peripheral vascular disease
Adult: Up to 50 mg by SC, IM, IV or slow intra-arterial inj.
Peptic ulcer, ischaemic heart disease, hypotension, stroke.
Special Precautions
Mitral stenosis. May activate stress ulcer. Pretreatment with antacid may prevent GI bleed in neonates. Pregnancy.
Adverse Reactions
Piloerection, headache, flushing, nausea, vomiting, diarrhoea, epigastric pain, tachycardia, cardiac arrhythmias, tingling, chilliness, shivering, sweating, oliguria, haematuria, metabolic alkalosis, MI, GI haemorrhage, burning sensation in the limb with intra-arterial inj.
Potentially Fatal: Blood dyscrasias, cardiotoxicity, renal failure.
Symptoms: Increased pilomotor activity, peripheral vasodilatation, skin flushing, hypotension and shock. Management: Admin IV fluid and place the patient's head low in the treatment of hypotension. Epinephrine should not be used as high-dose tolazoline may result in further reduction in BP, followed by an exaggerated rebound.
Drug Interactions
Disulfiram-like reaction with alcohol. Decreased pulmonary vasodilatory effects of tolazoline with H2-receptor antagonists. Increased risk of paradoxical hypotension with sympathomimetics.
Description: Tolazoline is a direct peripheral vasodilator with some α-adrenoceptor-blocking activity. Besides stimulating smooth muscle in the GI tract and increasing GI secretion, it can also cause mydriasis and heart stimulation.
Excretion: Excreted in urine mainly as unchanged drug. Half-life in neonates: 3-10 hr.
Store between 15-30°C (59-86°F).
Store between 15-30°C (59-86°F).
Store between 15-30°C (59-86°F).
MIMS Class
Peripheral Vasodilators & Cerebral Activators
Disclaimer: This information is independently developed by MIMS based on Tolazoline hydrochloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in